Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Remitly Global (NASDAQ:RELY – Get Free Report)‘s stock had its “outperform” rating reaffirmed by analysts at William Blair in a research note issued on Thursday,RTT News reports. Several other ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Cardiff Oncology (CRDF – Research Report). The company’s ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...